Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
about
Urinary Markers of Tubular Injury in HIV-Infected PatientsDrug-Induced Metabolic AcidosisDual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsThe role of drug transporters in the kidney: lessons from tenofovirWhen to start antiretroviral therapy: as soon as possibleManagement of patients with hepatitis B in special populationsLow body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse eventsA randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individualsPilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimenBone health in HIV and hepatitis B or C infectionsSystemic preexposure prophylaxis for HIV: translating clinical data to clinical practice.Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicityBrief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsCritical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients.Is HIV a model of accelerated or accentuated aging?Dietary supplementation with essential amino acids boosts the beneficial effects of rosuvastatin on mouse kidneyAntiretroviral therapy: current drugsRenal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapineAASLD guidelines for treatment of chronic hepatitis B.Albuminuria is associated with elevated acute phase reactants and proinflammatory markers in HIV-infected patients receiving suppressive combination antiretroviral therapy.Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.Association of urine α1-microglobulin with kidney function decline and mortality in HIV-infected womenVirological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.Focal bone lesions in HIV-positive patient treated with tenofovirHigher risk of renal impairment associated with tenofovir use amongst people living with HIV in India: a comparative cohort analysis between Western India and United Kingdom.A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Albuminuria Is Associated with Traditional Cardiovascular Risk Factors and Viral Load in HIV-Infected Patients in Rural South Africa.Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.Urinary biomarkers of kidney diseases in HIV-infected children.Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-retroviral therapy in two public health facilities in Uganda.Tenofovir-associated nephrotoxicity in patients with chronic hepatitis B: two cases.Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis BViability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.Pharmacists as providers of HIV pre-exposure prophylaxis.The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART RegimensHigher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV.Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting.
P2860
Q26738912-1EC40ED9-5065-48A8-8446-E2BAD2865C3EQ26766204-9BC790EC-E298-4EAE-AB57-112F56912AABQ26768591-5F259233-3777-49C1-95F7-9CF68708B6ACQ26866489-8E320E52-4B96-45B7-B1F7-454F02A6D1BBQ27006767-1304B324-A26F-4506-9B36-6A94C11C759AQ27016136-C94D67A8-C274-4670-8397-9C1CC1D4E94FQ28535587-74C48891-D016-4F56-917B-15159F24A34AQ28543212-2EF1A5A9-A741-4D59-B3A8-8ACF1D8C7DBDQ28741214-97981CA2-FEDD-4E0B-B995-7679CA367F66Q30238946-E73054BC-8F9F-48E1-90BF-90004126D201Q30744184-E97D584B-855C-4C2E-AF2D-8B81CAB559A7Q33551834-70FC60C7-9269-4CFC-8CE8-54739478574DQ33669829-7FB32986-0937-4857-A40A-1B4D5F6B3C4BQ33680234-4491A825-B60B-48DB-85C0-E024A7B47433Q33734997-CDAB607A-25EA-4A27-AF52-1352D9AB8F52Q33768015-5F7ADC41-EECD-432D-BEFF-2B93CBCF0C41Q33792651-1ADA22EC-F6B2-448A-817B-FB2D59476CC6Q34045750-F189AAF5-183F-4554-BC46-56D336B2CD52Q34085926-2BA90705-0BDF-46A5-9695-EBC1D32B7B72Q34250879-37ED32A5-AE6C-4842-BF57-32E04853539AQ34501660-4E2BB630-7C68-4D59-9720-30CC6D6E4846Q34606582-F5CBA891-2C27-4704-844C-8A48F8168966Q34787977-EEB54106-296D-4AD5-BFFA-3DE96E6F5E4EQ34828514-444EA4CA-F05A-44FC-BD8D-8D3FADFEBF31Q34906495-9C925F47-C011-4481-9BFF-7688DB7AF435Q35112499-BC1CD066-C539-46E6-BDD8-8102F8504E46Q35134488-EBDAFBB0-F9F5-41C2-84AD-5B4BC0DBFB67Q35149475-FE7E1CA2-344E-4267-8EB3-24236CB18821Q35566732-EB1A07E2-11D8-48CA-85AA-01590CF20D0FQ35756256-58AA77F6-56EE-48EE-88FC-C422D6700D6DQ35841996-CE76957A-9470-4BDD-8035-61933A40D67AQ35934081-D6F43547-2369-46B5-974D-EE74638F7F96Q35981062-947B055F-EAA2-45BE-B1B9-B3986CB293CBQ36067839-A2943AD7-C4B1-4FBA-AF07-41C4160453FEQ36238754-4941FAE9-E9CC-49BF-837F-4A1FF27A414AQ36275141-6B821341-5D24-4FD1-8269-B1B779FE04FAQ36409750-49C02AA3-6F3C-4922-869D-410905D06EB6Q36472367-CD991995-7766-4DD1-90DD-B21980167828Q36663586-A3394593-C94C-42F7-A4FB-E5E02C639313Q36722728-ACF019C8-A037-4E6F-9B38-C8FD9BCC93CC
P2860
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
@en
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
@nl
type
label
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
@en
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
@nl
prefLabel
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
@en
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
@nl
P2093
P1476
Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.
@en
P2093
Andrew M Hall
Bruce M Hendry
Dorothea Nitsch
John O Connolly
P304
P356
10.1053/J.AJKD.2011.01.022
P577
2011-03-23T00:00:00Z